After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last year’s levels.
The slowdown comes amid a broader pullback in global venture funding. Across all sectors, investment hit its zenith in November and has been cresting downward since. On the exit front, meanwhile, the pace of venture-backed IPOs has slowed to a crawl. READ MORE